Bone metabolism in healthy ambulatory control premenopausal women and in epileptics on anti-convulsant drugs

East Afr Med J. 2010 Apr;87(4):151-5. doi: 10.4314/eamj.v87i4.62411.

Abstract

Background: Long term anti-epileptic drug use causes multiple abnormalities in calcium and bone metabolism that have been documented in both institutionalised and ambulatory patients.

Objective: To assess bone metabolism in ambulatory females of reproductive age, on antiepileptic drugs.

Design: Cross sectional comparative study.

Subjects: Ambulatory females in reproductive age group with epilepsy and on regular follow up were compared to healthy females of similar ages not on any treatment.

Results: The mean duration of treatment for epilepsy was eight years (+/- 6.3). Majority of the patients were on enzyme inducing drugs like phenobarbital, phenytoin, carbamazepine and valproate, either alone or in combination with non-enzyme inducers like lamotrigine (98.2%). There was a significantly lower mean serum calcium and a higher alkaline phosphatase level among the patients (P = 0.002 and 0.0001 respectively) than among the comparators. The urinary marker of bone loss (mean urine calcium excretion) was also significantly raised among the patients (P=0.003). The mean lumbar BMDT-score results were not significantly different in the two groups.

Conclusions: Long-term anti-epileptic drug use significantly affects biochemical parameters of bone metabolism. These effects on bone biochemistry markers were not reflected in lumbar spine BMD in this study.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Anticonvulsants / therapeutic use*
  • Bone Density
  • Bone Remodeling / physiology*
  • Case-Control Studies
  • Cross-Sectional Studies
  • Epilepsy / drug therapy*
  • Epilepsy / metabolism*
  • Female
  • Humans
  • Middle Aged
  • Premenopause / metabolism*
  • Sex Factors
  • Young Adult

Substances

  • Anticonvulsants